References:
1. Feng X, Sureda A, Jafari S, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923-1951.
2. Firouzi S, Malekahmadi M, Ghayour-Mobarhan M, Ferns G, Rahimi HR. Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action. Diabetes, metabolic syndrome and obesity : targets and therapy. 2018;11:699-705.
3. Hu X, Zhang Y, Xue Y, Zhang Z, Wang J. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. American journal of translational research. 2018;10(11):3322-3329.
4. Zhang YP, Deng YJ, Tang KR, et al. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. Current medical science. 2019;39(1):37-43.
5. Zhu X, Bian H, Wang L, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free radical biology & medicine. 2019;141:192-204.
6. Gu JJ, Gao FY, Zhao TY. A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2012;63(5):505-513.
7. Liang KW, Yin SC, Ting CT, et al. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. European journal of pharmacology. 2008;590(1-3):343-354.
8. Cho BJ, Im EK, Kwon JH, et al. Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1/2 pathway in vascular smooth muscle cells. Molecules and cells. 2005;20(3):429-434.
9. Lee S, Lim HJ, Park HY, Lee KS, Park JH, Jang Y. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis. 2006;186(1):29-37.
10. Bai M, Liu Y, Zhou F, et al. Berberine inhibits glucose oxidation and insulin secretion in rat islets. Endocrine journal. 2018;65(4):469-477.
11. Chen DL, Yang KY. Berberine Alleviates Oxidative Stress in Islets of Diabetic Mice by Inhibiting miR-106b Expression and Up-Regulating SIRT1. Journal of cellular biochemistry. 2017;118(12):4349-4357.
12. Wang C, Wang Y, Ma SR, et al. Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3. Scientific reports. 2019;9(1):13415.
13. Lin YC, Lee YC, Lin YJ, Lin JC. Berberine Promotes Beige Adipogenic Signatures of 3T3-L1 Cells by Regulating Post-transcriptional Events. Cells. 2019;8(6).
14. Jiang D, Wang D, Zhuang X, et al. Berberine increases adipose triglyceride lipase in 3T3-L1 adipocytes through the AMPK pathway. Lipids Health Dis. 2016;15(1):214.
15. Ma X, Chen Z, Wang L, et al. The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine. Frontiers in pharmacology. 2018;9:782.
16. Krishan S, Richardson DR, Sahni S. Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Molecular pharmacology. 2015;87(3):363-377.
17. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell metabolism. 2005;1(1):15-25.
